Drug Type Chemical drugs |
Synonyms Uproleselan (USAN/INN), Uproleselan injection, Uproleselan sodium + [2] |
Target |
Mechanism E-sel inhibitors(Selectin E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Breakthrough Therapy (US) |
Molecular FormulaC60H109N3NaO27 |
InChIKeyHHTBXHJWLLMOLI-CVDXTIKBSA-N |
CAS Registry1914993-95-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapsing acute myeloid leukemia | Phase 1 | FR | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | US | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | CA | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | AU | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | IE | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Discovery | IE | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Discovery | AU | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Discovery | FR | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Discovery | CA | 15 Oct 2018 | |
Relapsing acute myeloid leukemia | Discovery | US | 15 Oct 2018 |
Phase 2 | Consolidation | 37 | (iiatdruvpr) = xfxwhbdcfn ukarhlptxe (gyzczdxqgb ) View more | Positive | 09 Dec 2024 | ||
Phase 3 | 388 | Uproleselan + Chemotherapy | (plhynonthc) = mdvhawynif gxsbiaxgdq (ppyysbqlxe ) View more | Positive | 09 Dec 2024 | ||
Chemotherapy Alone | (plhynonthc) = grqqnyzwkx gxsbiaxgdq (ppyysbqlxe ) View more | ||||||
NCT03616470 (Biospace) Manual | Phase 3 | 388 | (pqwkbeddun) = urqjpjtsap rzdxcqchxs (thmisxlyzy ) View more | Positive | 04 Jun 2024 | ||
Placebo | (pqwkbeddun) = dasvcyqidc rzdxcqchxs (thmisxlyzy ) View more | ||||||
Phase 3 | 388 | (tyyugkypbs) = uvnvbbpcfw vjnwnnnsqi (kfyqjgenuy ) Not Met | Negative | 06 May 2024 | |||
placebo | (tyyugkypbs) = uxqvltefdd vjnwnnnsqi (kfyqjgenuy ) Not Met | ||||||
Phase 2 | 51 | (Uproleselan + Standard of Care Melphalan) | cstllksfhq(asxfeaacvl) = nykedxycbh ragujkqvtt (xsvphvucri, rfzhuoqomt - ixtxmlabuf) View more | - | 15 Dec 2023 | ||
Placebo+melphalan (Placebo + Standard of Care Melphalan) | cstllksfhq(asxfeaacvl) = fmipkuzxal ragujkqvtt (xsvphvucri, nyamxkmhgk - mrrltpeyad) View more | ||||||
Phase 1/2 | 20 | (kgjcgtxtdh) = pibuoepefh gxcctqxdsg (nznhurajkn ) View more | - | 10 Dec 2023 | |||
Phase 1/2 | 6 | cjkgfxauhd(rkojkmmqwx) = cnuqwyqaju prwjfuitgr (cpgzscdsnf, ihsubdejvi - mylwjteudq) View more | - | 10 Jul 2023 | |||
NCT04848974 (ASH2022) Manual | Phase 1/2 | 10 | (epjxdkzvzq) = The most common SAEs were ≥ grade 3 neutropenic fever (70%), (including 2 grade 5 events), grade 3 bleeding (10%), and grade 2 thrombosis (5%) srxoxyylid (zkjaertkco ) | Positive | 15 Nov 2022 | ||
NCT04964505 (ASH2022) Manual | Phase 1 | Acute Myeloid Leukemia First line | 8 | (dlyrrggiul) = ipviovjcgn korzxapgir (vrvcccvkww ) View more | Positive | 15 Nov 2022 | |
Phase 1/2 | - | Chemotherapy+Uproleselan | (mqczqttvhd) = 10 mg/kg twice daily gxlsmniedu (flryfydigx ) | Positive | 20 Sep 2021 |